ESPR - CIK 0001434868
Esperion Therapeutics, Inc. trades as ESPR. In its fiscal 2025 annual report the company posted revenue of $403.13M, up 21.3% from the prior year and net income of -$22.68M. This page tracks Esperion Therapeutics, Inc. through 885 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin expanded from -65.5% to -5.6% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-08 |
| Proxy materials | DEFA14A | 2026-05-04 |
| Proxy materials | DEFA14A | 2026-05-01 |
| Proxy materials | DEFA14A | 2026-05-01 |
| Major company event | 8-K | 2026-05-01 |
| SCHEDULE 13G | - | 2026-04-22 |
| Annual report to shareholders | ARS | 2026-04-16 |
| Proxy materials | DEFA14A | 2026-04-16 |
The largest companies sharing Esperion Therapeutics, Inc.'s SEC industry classification (pharmaceutical preparations).
Esperion Therapeutics, Inc. reported revenue of $403.13M for fiscal year 2025, an increase of 21.3% year over year.
In its latest fiscal year Esperion Therapeutics, Inc. reported a net loss of $22.68M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.